N339908 N3 Ruling Active

The tariff classification of Ozanimod (CAS No. 1306760-87-1) in bulk form, from Taiwan

Issued May 30, 2024 by U.S. Customs and Border Protection.

Tariff classification

HTS codes: 2934.99.3000

Headings: 2934

Product description

, Ltd. Ozanimod is a sphingosine l-phosphate receptor modulator. It is an immunomodulatory drug indicated for the treatment of multiple sclerosis, ulcerative colitis, and inflammatory bowel disease.

CBP rationale

The applicable subheading for the Ozanimod in bulk form will be 2934.99.3000, Harmonized Tariff Schedule of the United States (HTSUS), which provides for “Nucleic acids and their salts, whether or not chemically defined; other heterocyclic compounds: Other: Other: Aromatic or modified aromatic: Other: Drugs.

Full text

N339908 May 30, 2024 CLA-2-29:OT:RR:NC:N3:138 CATEGORY: Classification TARIFF NO.: 2934.99.3000 Yaling Lo Pharmaports LLC 1 E Uwchlan Ave., Suite 116 Exton, PA 19341 RE:  The tariff classification of Ozanimod (CAS No. 1306760-87-1) in bulk form, from Taiwan Dear Ms. Lo: In your letter dated May 3, 2024, you requested a tariff classification ruling on behalf of Chunghwa Chemical Synthesis & Biotech Co., Ltd. Ozanimod is a sphingosine l-phosphate receptor modulator.  It is an immunomodulatory drug indicated for the treatment of multiple sclerosis, ulcerative colitis, and inflammatory bowel disease.   The applicable subheading for the Ozanimod in bulk form will be 2934.99.3000, Harmonized Tariff Schedule of the United States (HTSUS), which provides for “Nucleic acids and their salts, whether or not chemically defined; other heterocyclic compounds: Other: Other: Aromatic or modified aromatic: Other: Drugs.” The rate of duty will be 6.5 percent ad valorem. Currently, Ozanimod is not listed in the Pharmaceutical Appendix to the Harmonized Tariff Schedule. Duty rates are provided for your convenience and are subject to change. The text of the most recent HTSUS and the accompanying duty rates are provided at https://hts.usitc.gov/. This merchandise may be subject to the Federal Food, Drug, and Cosmetic Act and/or The Public Health Security and Bioterrorism Preparedness and Response Act of 2002 (The Bioterrorism Act), which are administered by the U.S. Food and Drug Administration (FDA). Information on the Federal Food, Drug, and Cosmetic Act, as well as The Bioterrorism Act, can be obtained by calling the FDA at 1-888-463-6332, or by visiting their website at www.fda.gov. The holding set forth above applies only to the specific factual situation and merchandise description as identified in the ruling request. This position is clearly set forth in Title 19, Code of Federal Regulations (CFR), Section 177.9(b)(1). This section states that a ruling letter is issued on the assumption that all of the information furnished in the ruling letter, whether directly, by reference, or by implication, is accurate and complete in every material respect. In the event that the facts are modified in any way, or if the goods do not conform to these facts at time of importation, you should bring this to the attention of U.S. Customs and Border Protection (CBP) and submit a request for a new ruling in accordance with 19 CFR 177.2. Additionally, we note that the material facts described in the foregoing ruling may be subject to periodic verification by CBP. This ruling is being issued under the provisions of Part 177 of the Customs and Border Protection Regulations (19 C.F.R. 177). A copy of the ruling or the control number indicated above should be provided with the entry documents filed at the time this merchandise is imported. If you have any questions regarding the ruling, please contact National Import Specialist Judy Lee at [email protected]. Sincerely, Steven A. Mack Director National Commodity Specialist Division

View original on CBP CROSS →

More rulings on the same tariff codes

Searching CBP rulings the smart way

TariffLens semantically searches all 200,000+ CBP rulings, surfaces the ones that actually match your product, and builds defensible classifications backed by ruling citations.

Book a demo →